House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Cardiology

Atrial fibrillation — 2024 ESC guidelines

ESC · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The ESC Essential Messages organize atrial fibrillation management around AF-CARE: comorbidity management, prevention of thromboembolism, symptom reduction and repeated evaluation. Shared decisions and continuing reassessment apply across anticoagulation, rate control and rhythm-control choices.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Confirm AF and assess the whole patient

  • Confirm clinical AF using an ECG device before initiating AF risk stratification and management. Initial evaluation includes history, symptom burden, blood tests, cardiac imaging, patient-reported outcomes and thromboembolic and bleeding risks. [1]
  • Use patient-centred, multidisciplinary shared care. Provide education for patients and caregivers, and avoid inequalities related to gender, ethnicity, disability or socioeconomic circumstances. [1]
  • Evaluate and manage associated conditions, including hypertension, heart failure, diabetes, obesity, sleep apnoea, inactivity and high alcohol intake. Comorbidity management is relevant to AF progression, treatment success and adverse outcomes. [1]

Base anticoagulation on individual thromboembolic risk

  • Use a locally validated risk tool or CHA2DS2-VA together with other risk factors, and reassess periodically when deciding on anticoagulation. [1]
  • For eligible patients, consider anticoagulation at CHA2DS2-VA 1 and recommend it at 2 or higher. Patients at low thromboembolic risk are the exception to routine oral-anticoagulant treatment. [1]
  • Prefer a DOAC over a vitamin K antagonist except in the stated groups with mechanical heart valves or mitral stenosis. The Essential Messages name apixaban, dabigatran, edoxaban and rivaroxaban. [1]
  • Use the standard full DOAC dose unless specific dose-reduction criteria are met. For vitamin K antagonists, the general INR range is 2.0–3.0 with more than 70% time in range. [1]
  • For patients eligible for a DOAC, switch from a vitamin K antagonist when intracranial-haemorrhage risk or poor INR control supports doing so. DOACs are not the substitute for patients with mechanical heart valves or mitral stenosis. Do not interpret this as routine switching of every stable older patient. [1]
  • Correct modifiable bleeding risk factors, but do not use a bleeding score to decide whether to start or withdraw anticoagulation. [1]
  • Avoid combining an anticoagulant with antiplatelet treatment unless there is an acute vascular event or a need for temporary treatment around a procedure. [1]

Match symptom treatment to cardiac status and preference

  • For rate control, beta-blockers or digoxin can be used at any ejection fraction; diltiazem or verapamil are options when LVEF is above 40%. Rate treatment may be acute initial therapy, an adjunct to rhythm control or the main symptom-control strategy. [1]
  • Consider rhythm control in suitable patients after discussing the benefits and risks of cardioversion, antiarrhythmic drugs and catheter or surgical ablation. [1]
  • For planned cardioversion, keep anticoagulation and safety central: the key message advises delaying cardioversion for AF lasting more than 24 hours and providing at least 3 weeks of anticoagulation first. Haemodynamic instability instead requires electrical cardioversion. Antiarrhythmic choices also require attention to toxicity and interactions. [1]
  • Use electrical cardioversion for haemodynamic instability. Otherwise choose electrical or pharmacological cardioversion according to patient characteristics and preferences. [1]
  • Long-term rhythm control is primarily for AF-related symptoms and quality of life. In selected groups, maintaining sinus rhythm can also be pursued to reduce morbidity or mortality. [1]
  • Continue anticoagulation according to individual thromboembolic risk irrespective of apparent rhythm-control success or whether the patient is currently in AF or sinus rhythm. [1]

Consider ablation and continue dynamic follow-up

  • Consider catheter ablation after antiarrhythmic drugs fail, or as a first-line option for paroxysmal AF. [1]
  • Consider endoscopic or hybrid ablation after failed catheter ablation, or as an alternative in persistent AF despite antiarrhythmic medication. [1]
  • AF ablation during cardiac surgery should be performed by experienced teams, particularly when mitral valve surgery is being undertaken. [1]
  • Reassess treatment periodically and look for new modifiable risks that may affect AF progression, quality of life or adverse outcomes. [1]

Limitations and use

  • This summary covers the official Essential Messages rather than the complete guideline. It does not supply all anticoagulant dose-reduction criteria, procedural exceptions or antiarrhythmic contraindications. The source’s evidence-gap section identifies research uncertainties; these are not additional treatment recommendations.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Atrial fibrillation — 2024 ESC guidelines — focused recommendation source

    Selected recommendation material consulted

Original guideline

Publication details

Issuing organisation
ESC
Resource type
Clinical guideline · House clinical summary

Earlier House summaries: atrial fibrillation esc

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Confirm AF and assess the whole patient
  • Base anticoagulation on individual thromboembolic risk
  • Match symptom treatment to cardiac status and preference
  • Consider ablation and continue dynamic follow-up
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House